Study #2023-0610
Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.
MD Anderson Study Status
Enrolling
Treatment Agent
SIRPant-M
Description
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Study phase:
Phase I
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-994-3163
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.